Cannon, Anthony J <br/><br/>
Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets.  [electronic resource] 

 -  Journal of managed care & specialty pharmacy  Feb 2020 
 - 143-153 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2376-1032 
<br/><br/><label>Standard No.: </label>10.18553/jmcp.2019.19035  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Blood Glucose--drug effects<br/>Cost-Benefit Analysis<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Drug Combinations<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemia--chemically induced<br/>Hypoglycemic Agents--administration & dosage<br/>Insulin Glargine--administration & dosage<br/>Insulin, Long-Acting--administration & dosage<br/>Liraglutide--administration & dosage<br/>Metformin--administration & dosage<br/>United States